Last modification: 2011/08/22

Autor(en) Titel Quelle Links
Zanella A, Bianchi P, Fermo E, Valentini G Hereditary pyrimidine 5'-nucleotidase deficiency: from genetics to clinical manifestations. British journal of haematology 2006, 133: 113    
Zahm SH, Ward MH Pesticides and childhood cancer. Environ Health Perspect 1998, 106 (Suppl 3): 893    
Zahn S, Sievers S, Alemazkour K, Orb S, Harms D, Schulz WA, Calaminus G, Göbel U, Schneider DT Imbalances of chromosome arm 1p in pediatric and adult germ cell tumors are caused by true allelic loss: a combined comparative genomic hybridization and microsatellite analysis. Genes, chromosomes & cancer 2006, 45: 995    
Zanella A, Bianchi P, Fermo E, Valentini G Hereditary pyrimidine 5'-nucleotidase deficiency: from genetics to clinical manifestations. British journal of haematology 2006, 133: 113    
Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2013, 9: 29    
Zapka P, Dörner E, Dreschmann V, Sakamato N, Kristiansen G, Calaminus G, Vokuhl C, Leuschner I, Pietsch T Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms. Journal of neuropathology and experimental neurology 2018, 77: 119    
Zeidler C, Schwinzer B, Welte K [Severe congenital neutropenia: trends in diagnosis and therapy]. Klinische Padiatrie 2000, 212: 145    
Zeidler C, Boxer L, Dale DC, Freedman MH, Kinsey S, Welte K Management of Kostmann syndrome in the G-CSF era. British journal of haematology 2000, 109: 490    
Zeidler C, Welte K Kostmann syndrome and severe congenital neutropenia. Seminars in hematology 2002, 39: 82    
Zeidler C, Schwinzer B, Welte K Congenital neutropenias. Reviews in clinical and experimental hematology 2003, 7: 72    
Zeidler, C Granulozytopenien. In: Gadner, H, Gaedicke, G, Niemeyer, C, Ritter, J (Hrsg.): Pädiatrische Hämatologie und Onkologie, Springer Medizin Verlag 2006, pp. 192    
Zeidler C, Welte K Hematopoietic growth factors for the treatment of inherited cytopenias. Seminars in hematology 2007, 44: 133    
Zeidler C, Welte K [Congenital bone marrow failure syndromes. The last 20 years by the example of congenital neutropenia]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007, 50: 1564    
Zeidler C, Germeshausen M, Klein C, Welte K Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. British journal of haematology 2009, 144: 459    
Zeidler L, Zimmermann M, Möricke A, Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L, Jäger S, Ratei R, Ludwig WD, Teigler-Schlegel A, Skokowa J, Koehler R, Bartram CR, Riehm H, Schrappe M, Welte K, Stanulla M Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. Haematologica 2012, 97: 402    
Zeidler C [Primary and secondary neutropenia]. Zeitschrift fur Rheumatologie 2013, 72: 663    
Zeidler C, Grote UA, Nickel A, Brand B, Carlsson G, Cortesão E, Dufour C, Duhem C, Notheis G, Papadaki HA, Tamary H, Tjønnfjord GE, Tucci F, Van Droogenbroeck J, Vermylen C, Voglova J, Xicoy B, Welte K Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry. Haematologica 2014, 99: 1395    
Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999, 17: 832    
Zeng L, Wang C, Jiang M, Chen K, Zhong H, Chen Z, Huang L, Li H, Zhang L, Choonara I Safety of ceftriaxone in paediatrics: a systematic review. Archives of disease in childhood 2020 Mar 6; ePub    
Zernikow B, Griessinger N, Fengler R [Practice of pain control in paediatric oncology--recommendations of the quality-monitoring group of the German Society for Paediatric Oncology and Haematology (GPOH)]. Schmerz (Berlin, Germany) 1999 Jun 11; 13: 213    
Zernikow B Schmerztherapie in der Kinderhämatologie, in Zernikow B: Schmerztherapie bei Kindern. Springer Verlag, Berlin, Heidelberg, New York 2001, 176    
Zernikow B, Bauer AB, Andler W Pain control in German pediatric oncology. An inventory. Schmerz (Berlin, Germany) 2002, 16: 140    
Zernikow B STOP dem Schmerz – Schmerz-Therapie in der Onkologischen Pädiatrie (STOP) – Ergebnisse eines bundesweiten Qualitätsmanagement-Programms. WIR Informationsschrift der Aktion für krebskranke Kinder e.V. (Bonn) 2004, 4: 19    
Zernikow B Schmerztherapie in der Kinderhämatonkologie, in Zernikow B: Schmerztherapie bei Kindern. Springer Medizin Verlag Heidelberg 3. Aufl. 2005, 217    
Zernikow B , Wamsler C, Schiessl C Palliativmedizin und Schmerztherapie bei krebskranken Kindern und Jugendlichen. Kinder- und Jugendarzt 2006, 10, 649    
Zernikow B, Schiessl C, Wamsler C, Janssen G, Griessinger N, Fengler R, Nauck F Practical pain control in pediatric oncology. Recommendations of the German Society of Pediatric Oncology and Hematology, the German Association for the Study of Pain, the German Society of Palliative Care, and the Vodafone Institute of Children's Pain Therapy and Palliative Care. Schmerz 2006, 20: 24    
Zernikow B, Smale H, Michel E, Hasan C, Jorch N, Andler W Paediatric cancer pain management using the WHO analgesic ladder--results of a prospective analysis from 2265 treatment days during a quality improvement study. European journal of pain 2006t; 10: 587    
Zernikow B, Hasan C, Hechler T, Huebner B, Gordon D, Michel E Stop the pain! A nation-wide quality improvement programme in paediatric oncology pain control. European journal of pain 2008, 12: 819    
Zernikow B Palliativmedizin und Schmerztherapie. in: C. P. Speer et al. (Hrsg.): Pädiatrie; Springer-Verlag GmbH Deutschland 2019    
Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008, 105: 19579    
Zhou AW, Knoche EM, Engle EK, Ban-Hoefen M, Kaiwar C, Oh ST Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia. The New England journal of medicine 2016, 375: 494    
Zhu K, Levine RS, Gu Y, Brann EA, Hall I, Caplan LS et al. Non-Hodgkin's lymphoma and family history of malignant tumor in a case -control study (United States). Cancer Causes Control 1998, 9: 77    
Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR Germline Mutations in Predisposition Genes in Pediatric Cancer. The New England journal of medicine 2015 Dec 10; 373: 2336    
Zils K, Ebner F, Ott M, Müller J, Baumhoer D, Greulich M, Rehnitz D, Rempen A, Schaetzle S, Wilhelm M, Bielack S Extraskeletal Osteosarcoma of the Breast in an Adolescent Girl. Journal of pediatric hematology/oncology 2012 Jan ; [Epub ahead of print]    
Zils K, Bielack S, Wilhelm M, Werner M, Schwarz R, Windhager R, Hofmann-Wackersreuther G, Andus T, Kager L, Kuehne T, Reichardt P, von Kalle T Osteosarcoma of the mobile spine. Annals of oncology 2013, Epub ahead of print    
Zils K, Bielack S Osteosarcoma After Bone Marrow Transplantation: Still a Challenge. Journal of pediatric hematology/oncology 2013, epub ahead of print    
Zils K, Klingebiel T, Behnisch W, Mueller HL, Schlegel PG, Fruehwald M, Suttorp M, Simon T, Werner M, Bielack S Osteosarcoma in patients with rothmund-thomson syndrome. Pediatric hematology and oncology 2015, 32: 32    
Zin F, Cotter JA, Haberler C, Dottermusch M, Neumann J, Schüller U, Schweizer L, Thomas C, Nemes K, Johann PD, Kool M, Frühwald MC, Paulus W, Judkins A, Hasselblatt M Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup. Brain pathology 2021,e12967    
Zirn B, Wittmann S, Graf N, Gessler M Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development. Cancer letters 2005, 220: 115    
Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 2005, 24: 5246    
Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N, Gessler M Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes, chromosomes & cancer 2006, 45: 565    
Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, Graf N, Eilers M, Gessler M Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. International journal of cancer 2006, 118: 1954    
Zirngibl F, Ivasko SM, Grunewald L, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Astrahantseff K, Andersch L, Schulte JH, Lode HN, Eggert A, Anders K, Hundsdoerfer P, Künkele A GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Journal for immunotherapy of cancer 2021, 9    
Zöllner SK, Amatruda JF, Bauer S, Collaud S, de Álava E, DuBois SG, Hardes J, Hartmann W, Kovar H, Metzler M, Shulman DS, Streitbürger A, Timmermann B, Toretsky JA, Uhlenbruch Y, Vieth V, Grünewald TGP, Dirksen U Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. Journal of clinical medicine 2021 Apr 14; 10    
Zöllner SK, Kauertz KL, Kaiser I, Kerkhoff M, Schaefer C, Tassius M, Jabar S, Jürgens H, Ladenstein R, Kühne T, Haveman LM, Paulussen M, Ranft A, Dirksen U Ewing Sarcoma as Secondary Malignant Neoplasm-Epidemiological and Clinical Analysis of an International Trial Registry. Cancers 2022, 14    
Zolk O, von dem Knesebeck A, Graf N, Simon T, Hero B, Abdul-Khaliq H, Abd El Rahman M, Spix C, Mayer B, Elsner S, Gebauer J, Langer T Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. JMIR research protocols 2022, 11:e27898    
Zotz R B, Scharf R E Rekombinanter Faktor VIIa bei Patienten mit Plättchenfunktionsstörungen oder Thrombozytopenien. Hämostaseologie 2007, 27; 237    
Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, Smith T, Jürgens H, Gadner H, Kovar H Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996, 14: 1245    
Zoubek A, Windhager R, Bielack S Osteosarkome. in: Gadner H, Gaedicke G, Niemeyer CH, Ritter J (Hrsg.): Pädiatrische Hämatologie und Onkologie Springer-Verlag 2006, 882    
Zschernack V, Jünger ST, Mynarek M, Rutkowski S, Garre ML, Ebinger M, Neu M, Faber J, Erdlenbruch B, Claviez A, Bielack S, Brozou T, Frühwald MC, Dörner E, Dreschmann V, Stock A, Solymosi L, Hench J, Frank S, Vokuhl C, Waha A, Andreiuolo F, Pietsch T Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta neuropathologica 2021, 141: 455    
Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. Journal of clinical oncology 2010, 28: 2584    
Zucchetti G, Rossi F, Chamorro Vina C, Bertorello N, Fagioli F Exercise program for children and adolescents with leukemia and lymphoma during treatment: A comprehensive review. Pediatric blood & cancer 2018, 65:e26924    
Zuna J, Moericke A, Arens M, Koehler R, Panzer-Grümayer R, Bartram CR, Fischer S, Fronkova E, Zaliova M, Schrauder A, Stanulla M, Zimmermann M, Trka J, Stary J, Attarbaschi A, Mann G, Schrappe M, Cario G Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia. British journal of haematology 2016, 173: 742    
Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M, Cazzaniga G, Cario G Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia 2022, 36: 2793    
zur Stadt, Harms D, Schluter S, Jorch N, Spaar H, Nurnberger W, Volpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study. Klin Pädiatr 2000, 212: 169    
zur Stadt, Harms D, Schluter S, Schrappe M, Goebel U, Spaar H, Janka G, Kabisch H MRD at the end of induction therapy in childhood acute lymphoblastic leukemia. Leukemia 2001, 15: 283    
Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach. International journal of oncology 2005, 27: 547    
Zwaan C, Kaspers G, Pieters R, Ramakers-van Woerden N, Den Boer M, Wunsche R, Rottier M, Hahlen K, van Wering E, Janka-Schaub G, Creutzig U, Veerman A Cellular drug resistance profiles in childhood acute myeloid leukemia. Blood 2000, 96: 2879    
Zwaan C, Kaspers G, Pieters R, Hahlen K, Huismans D, Zimmermann M, Harbott J, Slater R, Creutzig U, Veerman A Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 2002, 100: 3352    
Zwaan C, Kaspers G, Pieters R, Hahlen K, Janka-Schaub G, van Zantwijk C, Huismans D, de Vries E, Rots M, Peters G, Jansen G, Creutzig U, Veerman A Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002, 99: 245    
Zwaan C, Meshinchi S, Radich J, Veerman A, Huismans D, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers G, Griesinger F FLT3 internal tandem duplication in 234 children with acute myeloid leukemia. Blood 2003, 102: 2387    
Zwaan C, Reinhardt D, Corbacioglu S, van Wering E, Bokkerink J, Tissing W, Samuelsson U, Feingold J, Creutzig U, Kaspers G Gemtuzumab ozogamicin. Blood 2003, 101: 3868    
Zwaan Ch, Kaspers G, Pieters R, Huismans D, Creutzig U, Hählen K, van Wering E, Veerman A Age-Related Differences in Cellular Drug Resistance in Children with Acute Myeloid Leukemia (AML). Haematology and Blood Transfusion 2003,IX: 291    
Zwaan Ch, Reinhardt D, Corbacioglu S, van Wering E, Bokkerink J, Tissing W, Samuelsson U, Feingold J, Creutzig U, Kaspers G Gemtuzumab ozogamicin. Blood 2003, 101: 3868    
Zwaan Ch, Reinhardt D, Jürgens H, Huismans D, Hahlen K, Smith O, Biondi A, van Wering E, Feingold J, Kaspers G Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia. Leukemia 2003, 17: 468    
Zwaan MC, Reinhardt D, Hitzler J, Vyas P Acute leukemias in children with down syndrome. Pediatric clinics of North America 2008, 55: 53    
Zwaan CM, Reinhardt D, Hitzler J, Vyas P Acute leukemias in children with Down syndrome. Hematology/oncology clinics of North America 2010, 24: 19    
Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ, International BFM Study Group on Paediatric AML Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British journal of haematology 2010, 148: 768    
Zylka-Menhorn V, Richter-Kuhlmann E, Meißner M RADIOAKTIVITÄT Folgen von Reaktorunfällen – Fakten und Vermutungen. Dtsch Arztebl 2011 108: A-700 / B-568 / C    
Zynda A, Reinmuth S, Pfitzer C, Hohmann C, Keil T, Borgmann-Staudt A Childhood leukemia and its impact on graduation and having children: results from a national survey. Leukemia & lymphoma 2012, 53: 2419    
70 items found

The literature database is sorted by the first author's last name - please choose from the alphabet. It comprises the references that were reported by the trial co-ordinating centres and those which are referenced in this information service, for example by the patient information texts.